StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)

Close on Nov 16, 2026Market cap $1.52BP/E –Yield –

Earnings

GeneDx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$123.10M
+5.5% on a year earlier
Diluted adjusted earnings per share, Q3 FY2026
$0.28
$0.49 a year earlier
Latest guidance
Raised
Nov 9, 2026 · 10 items

Quarterly results

Revenue and earnings per share from each of GeneDx's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026after the close$123.10M+5.5%-$0.41$0.28Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026during market hours$114.40M+11.4%-$0.60$0.01Release
Q1 FY2026ended Mar 31, 2026May 4, 2026during market hours$102.30M+17.5%-$2.16-$0.28Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026before the open$121.00M+27.0%-$0.61$0.14Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025before the open$116.70M+51.8%-$0.27$0.49Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025before the open$102.70M+45.7%$0.36–Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025before the open$87.10M+39.6%––Release
Q4 FY2024ended Dec 31, 2024Feb 18, 2025before the open$95.30M+66.0%––Release
Q3 FY2024ended Sep 30, 2024Oct 29, 2024before the open$76.90M+44.3%––Release
Q2 FY2024ended Jun 30, 2024Jul 30, 2024during market hours$70.50M+44.8%-$1.10–Release
Q1 FY2024ended Mar 31, 2024Apr 29, 2024during market hours$62.40M+44.8%-$0.78–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

GeneDx's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueQ4 FY2026$135.00M–NewNov 9, 2026
Adjusted gross marginnon-GAAPQ4 FY202671%–NewNov 9, 2026
Adjusted net incomenon-GAAPQ4 FY2026$12.00M–NewNov 9, 2026
Exome and genome volumeQ4 FY202634,500–NewNov 9, 2026
Exome and genome revenueFY2026+17%–NewNov 9, 2026
Exome and genome revenueFY2026+20%–NewAug 3, 2026
RevenueFY2026$475.00M – $490.00M–NewNov 9, 2026
RevenueFY2026$475.00M – $490.00M$475.00M – $490.00MReaffirmedAug 3, 2026
RevenueGAAPFY2026$540.00M – $555.00M–NewFeb 23, 2026
Adjusted gross marginnon-GAAPFY202671%70%RaisedNov 9, 2026
Adjusted gross marginnon-GAAPFY202670%70%ReaffirmedAug 3, 2026
Adjusted net incomenon-GAAPFY2026$12.00M–NewNov 9, 2026
Exome and genome volumeFY2026+28%–LoweredNov 9, 2026
Exome and genome volumeFY2026+30%–RaisedAug 3, 2026
Growth in exome and genome revenueFY2026+20%+33% – +35%LoweredMay 4, 2026
Growth in exome and genome revenueFY2026+33% – +35%–NewFeb 23, 2026
Growth in exome and genome volumeFY2026+30%+33% – +35%LoweredMay 4, 2026
Growth in exome and genome volumeFY2026+33% – +35%–ReaffirmedFeb 23, 2026

Guidance vs results

The last range GeneDx gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$122.00M – $124.00M$123.10MWithin range
Q2 FY2026Revenue$110.00M – $112.00M$114.40MAbove range
FY2025Revenue$425.00M – $428.00M$427.50MΣ4QWithin range

Guidance history

Every forecast GeneDx put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 9, 2026Adjusted gross marginQ4 FY202671%New
Nov 9, 2026Adjusted gross marginFY202671%Raised
Nov 9, 2026Exome and genome volumeQ4 FY202634,500New
Nov 9, 2026Adjusted net incomeQ4 FY2026$12.00MNew
Nov 9, 2026Exome and genome volumeFY2026+28%Lowered
Nov 9, 2026Adjusted net incomeFY2026$12.00MNew
Nov 9, 2026RevenueQ4 FY2026$135.00MNew
Nov 9, 2026Exome and genome revenueQ4 FY2026$121.00MLowered
Nov 9, 2026Exome and genome revenueFY2026+17%New
Nov 9, 2026RevenueFY2026$475.00M – $490.00MNew
Aug 3, 2026Adjusted gross marginFY202670%Reaffirmed
Aug 3, 2026Adjusted gross marginQ3 FY202670%New
Aug 3, 2026Exome and genome volumeFY2026+30%Raised
Aug 3, 2026Exome and genome volumeQ3 FY202633,200New
Aug 3, 2026Adjusted net incomeQ3 FY2026$2.00MNew
Aug 3, 2026Exome and genome revenueFY2026+20%New
Aug 3, 2026RevenueFY2026$475.00M – $490.00MReaffirmed
Aug 3, 2026RevenueQ3 FY2026$122.00M – $124.00MNew
Aug 3, 2026Exome and genome revenueQ3 FY2026$110.00M – $112.00MLowered
May 4, 2026Adjusted gross marginFY202670%Reaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases GeneDx filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. Results
  4. Results
  5. Results
  6. Update
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?